SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Gufic Biosciences - Quaterly Results

09 Feb 2022 Evaluate
The company's total revenue for the quarter ended December 2021 saw a slight change in the total revenue, having registered a total revenue of Rs. 1720.65 millions.The company has announced a 36.01% increase in its profits to Rs . 210.34  millions for the  quarter ended December 2021 compared to Rs. 154.65 millions in the corresponding quarter in the previous year.The company reported a good operating profit of 342.49 millions compared to 274.55 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202112 202012 % Var 202112 202012 % Var 202103 202003 % Var
Sales 1720.65 1665.57 3.31 6169.62 3557.70 73.42 4876.99 3788.37 28.74
Other Income 15.30 0.33 4536.36 30.63 30.77 -0.45 37.33 57.90 -35.53
PBIDT 342.49 274.55 24.75 1172.59 632.50 85.39 876.52 579.06 51.37
Interest 10.32 37.79 -72.69 37.90 107.61 -64.78 136.33 139.15 -2.03
PBDT 332.17 236.76 40.30 1134.69 524.89 116.18 740.19 439.91 68.26
Depreciation 44.84 32.23 39.13 128.07 118.26 8.30 163.08 138.65 17.62
PBT 287.33 204.53 40.48 1006.62 406.63 147.55 577.11 301.26 91.57
TAX 76.99 49.88 54.35 250.86 93.02 169.68 134.80 74.38 81.23
Deferred Tax 4.29 2.15 99.53 -4.14 1.39 -397.84 20.11 8.85 127.23
PAT 210.34 154.65 36.01 755.76 313.61 140.99 442.31 226.88 94.95
Equity 96.95 96.95 0.00 96.95 96.95 0.00 96.95 77.83 24.57
PBIDTM(%) 19.90 16.48 20.75 19.01 17.78 6.91 17.97 15.29 17.58

Gufic Biosciences Share Price

295.65 -5.65 (-1.88%)
20-Apr-2026 14:56 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.15
Dr. Reddys Lab 1234.30
Cipla 1232.95
Zydus Lifesciences 938.40
Lupin 2329.85
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×